Home / Market News / $DNA

$DNA news and market catalysts

The 9 most recent market catalysts affecting $DNA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

9 catalysts 1 high impact 3 bullish 2 bearish Biotechnology
Nov 7, 2026 Corporate Catalyst Bearish Impact 65
TD Cowen Downgrades Ginkgo Bioworks to Hold From Buy
TD Cowen downgraded Ginkgo Bioworks (DNA) from a 'Buy' to a 'Hold' rating, establishing a new price target of $11. This change in analyst sentiment is significant because it signal…
Nov 5, 2026 Corporate Catalyst Bullish Impact 80
Ginkgo Bioworks Reports Q3 2026 Financial Results and First Autonomous Lab Sale
Ginkgo Bioworks (DNA) reported a mixed Q3 2026, with revenue declining by 5.7% year-over-year, which is a negative signal for top-line growth. However, the substantial narrowing of…
Oct 30, 2026 Corporate Catalyst Neutral Impact 55
Ginkgo Bioworks to Review Q3 2026 Performance on November 5
Ginkgo Bioworks (DNA) has filed an 8-K to announce its Q3 2026 earnings call and Q&A session on November 5, 2026. This is a standard corporate disclosure, providing investors with …
Oct 9, 2026 Corporate Catalyst Neutral Impact 65
What's Going on With Ginkgo Bioworks Stock on Friday?
Ginkgo Bioworks (DNA) announced two significant developments: a partnership with the National Science Foundation's X-Labs program to provide remote lab access for research teams, a…
Oct 9, 2026 Corporate Catalyst Bullish Impact 75
Ginkgo Bioworks shares are trading higher after the company announced that it will provide in-kind access to its autonomous laboratory in Boston to support the National Science Foundation’s X-Labs program.
This announcement is a significant positive catalyst for Ginkgo Bioworks. Providing in-kind access to its advanced lab facilities for a prestigious National Science Foundation prog…
Oct 8, 2026 Corporate Catalyst Neutral Impact 55
Ginkgo Bioworks To Integrate Araceli Biosciences' Endeavor High-Content Imaging Instrument Into Nebula, The Company's Autonomous Lab
Ginkgo Bioworks announced the integration of Araceli Biosciences' Endeavor high-content imaging system into its Nebula autonomous lab. This is a strategic move to enhance Ginkgo's …
Sep 16, 2026 Corporate Catalyst Bullish Impact 75
Ginkgo Bioworks Announces Ginkgo Datapoints Agreement With Eli Lilly's TuneLab To Provide Small Molecule And Antibody Developability Testing
This headline represents a significant corporate catalyst for Ginkgo Bioworks (DNA), as securing a partnership with a pharmaceutical giant like Eli Lilly (LLY) validates its techno…
Sep 4, 2026 Corporate Catalyst Neutral Impact 55
BTIG Reiterates Sell on Ginkgo Bioworks Holdings, Maintains $5 Price Target
This 8-K filing discloses that BTIG analyst Mark Massaro has reiterated a 'Sell' rating on Ginkgo Bioworks Holdings (DNA) and maintained a $5 price target. This action signals a co…
Aug 7, 2026 Corporate Catalyst Bearish Impact 65
TD Cowen Downgrades Ginkgo Bioworks Holdings to Hold, Lowers Price Target to $9
TD Cowen analyst Brendan Smith downgraded Ginkgo Bioworks Holdings (DNA) from a 'Buy' rating to a 'Hold' rating and simultaneously lowered the price target from $12 to $9. This act…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.